Trials / Completed
CompletedNCT00079833
Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome
A Phase III, Multicenter, Open-Label Study To Evaluate the Control of Gastric Acid Secretion With Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome For 12 Months
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 25 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research study will determine if esomeprazole, when administered twice daily at 40, 80, or 120 mg doses, can control excessive stomach acid secretion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Esomeprazole magnesium (Nexium) |
Timeline
- Start date
- 2003-11-01
- Completion
- 2005-07-01
- First posted
- 2004-03-17
- Last updated
- 2010-11-19
Locations
8 sites across 2 countries: United States, France
Source: ClinicalTrials.gov record NCT00079833. Inclusion in this directory is not an endorsement.